Skip to main content

Table 5 Multivariate analysis for patients receiving immunotherapy (n = 5807)

From: Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis

 

Hazard Ratio

95% Confidence Interval

p-value

Sex

Male

1.00

Ref

< 0.0001

Female

0.79

0.75–0.84

Age

18–59

1.00

Ref

< 0.0001

60–69

1.08

1.01–1.17

70–79

1.14

1.05–1.24

80+

1.26

1.09–1.46

Comorbidity

0

1.00

Ref

< 0.0001

1

1.15

1.07–1.23

> 2

1.25

1.12–1.40

Histology

Adenocarcinoma

1.00

Ref

< 0.0001

Non-adenocarcinoma

1.15

1.06–1.23

Race

White

1.00

Ref

0.012

Non-white

0.89

0.82–0.98

Insurance

Uninsured

1.00

Ref

0.079

insured

0.86

0.72–1.02

Facility Type

Academic

1.00

Ref

< 0.0001

Nonacademic

1.26

1.18–1.34

Radiation

No Radiation

1.00

Ref

< 0.0001

EBRT

1.37

1.29–1.46

SRT

0.78

0.66–0.93